Highlights Genocea Biosciences, Inc.

Equities

GNCAQ

US3724274010

Market Closed - OTC Markets Other stock markets 11:32:30 2024-04-30 am EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-99.00%

2023	Genocea Biosciences, Inc. Went Out of Business	CI
2023	Liquidation Plan Approved for Genocea Biosciences, Inc.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
Genocea Biosciences, Inc. Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022	22-04-08	CI
Genocea Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-03-10	CI
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting	22-03-08	CI
Genocea Biosciences, Inc. Enters into an R&D Collaboration and Option Agreement with Janssen Biotech, Inc	22-01-04	CI
Genocea Biosciences Provides Corporate Update	22-01-04	CI
Genocea Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-28	CI
Genocea Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-28	CI
Genocea Biosciences, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-07-29	CI
Genocea Biosciences, Inc. Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy	21-07-13	CI
Genocea Biosciences, Inc. Presents Promising Long-Term Results from Gen-009 Neoantigen Vaccine Phase 1 Trial At Asco 2021	21-06-04	CI
Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29	CI
Genocea Biosciences, Inc. Provides Update on Gen-011 Phase 1/2A Clinical Trial	21-04-29	CI
Genocea Biosciences, Inc. to Present Novel Preclinical Inhibigen™ Data	21-04-10	CI
Genocea Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	21-02-11	CI
Genocea Biosciences, Inc. Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS Platform	21-01-28	CI
Genocea Biosciences, Inc. Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020	20-11-09	CI
Genocea Biosciences, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-29	CI
Genocea Announces FDA Acceptance of GEN-011 IND Application	20-09-22	CI
Genocea Biosciences, Inc to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint Inhibitors	20-07-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Genocea Biosciences, Inc.

Equities

GNCAQ

US3724274010

Highlights

Filters